Fremanezumab is a prescription medicine indicated for the preventive treatment of migraine in adults, and the preventive treatment of episodic migraine in pediatric patients, among other approved uses. It is available as injection for subcutaneous use. MedsAcross supplies Fremanezumab for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
From the regulator-approved product information. Each section names its source.
AJOVY is indicated for: the preventive treatment of migraine in adults, and the preventive treatment of episodic migraine in pediatric patients who are 6 to 17 years of age and who weigh 45 kg or more. AJOVY is a calcitonin gene-related peptide antagonist indicated for: the preventive treatment of migraine in adults, and the preventive treatment of episodic migraine in pediatric patients who are 6 to 17 years of age and who weigh 45 kg or more.
Source: US FDA prescribing information
Fremanezumab-vfrm is a humanized monoclonal antibody that binds to calcitonin gene-related peptide (CGRP) ligand and blocks its binding to the receptor.
Source: US FDA prescribing information
For subcutaneous use only. Recommended dosage: Adults: Two subcutaneous dosing options of AJOVY are available to administer the recommended dosage, 225 mg monthly or 675 mg every 3 months (quarterly). The 675 mg quarterly dosage is administered as three consecutive injections of 225 mg each. Pediatric patients 6 to 17 years of age and who weigh 45 kg or more: 225 mg monthly. Administer in the abdomen, thigh, or upper arm subcutaneously. See Dosage and Administration for important administration instructions.
Source: US FDA prescribing information
AJOVY is contraindicated in patients with serious hypersensitivity to fremanezumab-vfrm or to any of the excipients. Reactions have included anaphylaxis and angioedema.
Source: US FDA prescribing information
Hypersensitivity Reactions: Most reactions were reported from within hours to one month after administration. If hypersensitivity occurs, consider discontinuing AJOVY and institute appropriate therapy. Constipation with Serious Complications: Serious complications of constipation may occur. Hypertension: New-onset or worsening of pre-existing hypertension may occur. Raynaud's Phenomenon: New-onset or worsening of pre-existing Raynaud’s phenomenon may occur.
Source: US FDA prescribing information
The following clinically significant adverse reactions are discussed in greater detail in other sections of the labeling: Hypersensitivity Reactions Constipation with Serious Complications Hypertension Raynaud’s Phenomenon The most common adverse reactions (≥5% and greater than placebo) were injection site reactions.
Source: US FDA prescribing information
Store refrigerated at 2°C to 8°C (36°F to 46°F) in the original outer carton to protect from light. If necessary, AJOVY may be kept in the original carton at room temperature up to 30°C (86°F) for a maximum of 7 days. After removal from the refrigerator, AJOVY must be used within 7 days or discarded. Once stored at room temperature, do not place back in the refrigerator. Do not freeze. Do not shake.
Source: US FDA prescribing information
For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
1 presentations of Fremanezumab, sorted by availability.
| Medicine | Manufacturer | Register | Availability |
|---|---|---|---|
| Ajovy 225 mg/1.5 mL injectionSubcutaneous Cold chain | Teva Pharmaceuticals | US FDA | Available on request |
1 brand names across 1 markets.
United States
Approval facts from US FDA, EMA and CDSCO data, and registration status by country where we hold register data.
Conditions linked to Fremanezumab in public data. This is not a list of approved uses, see the clinical information.
Yes, on request. MedsAcross lists 1 presentations of Fremanezumab and sources them for licensed hospitals, importers and physicians against valid import documents.
The catalogue lists 1 brand names for Fremanezumab, including Ajovy.
Yes. The US FDA first approved Fremanezumab on 14 September 2018, according to Drugs@FDA.
Yes. Fremanezumab has a central EU marketing authorisation (status: authorised), according to European Medicines Agency data.
At least one listed presentation of Fremanezumab must be kept cold, so it is shipped in temperature-controlled packaging. Check the storage line on each presentation.
Fremanezumab is classified under ATC code N02CD03 (Fremanezumab).
Tell us the strength, quantity and destination country. Our team replies with availability, lead time and the import documents needed.